CAS Number77671-31-9
SynonymsFenoximone; Enoximonum [Latin]; 5-methyl-4-(4-(methylthio)benzoyl)-1H-imidazol-2(3H)-one; 4-Methyl-5-[4-(methylsulfanyl)benzoyl]-1,3-dihydro-2H-imidazol-2-one; Enoximona; MFCD00867130; Perfane; Enoximonum; Enoximona [Spanish]; 1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-one; Enoximone; Perfan
Molecular FormulaC12H12N2O2S
Molecular Weight248.30
Purity98.00%
Density1.3±0.1 g/cm3
Melting Point255-258°C
Appearancesolid
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 77671-31-9 |
| Catalog No. | 2A-9010331 |
| Chinese Name | 依诺昔酮 |
| Synonyms | Fenoximone; Enoximonum [Latin]; 5-methyl-4-(4-(methylthio)benzoyl)-1H-imidazol-2(3H)-one; 4-Methyl-5-[4-(methylsulfanyl)benzoyl]-1,3-dihydro-2H-imidazol-2-one; Enoximona; MFCD00867130; Perfane; Enoximonum; Enoximona [Spanish]; 1,3-dihydro-4-methyl-5-[4-(methylthio)benzoyl]-2H-imidazol-2-one; Enoximone; Perfan |
| Molecular Formula | C12H12N2O2S |
| Molecular Weight | 248.30 |
| Purity | 98.00 |
| Density | 1.3±0.1 g/cm3 |
| Melting Point | 255-258°C |
| Appearance | solid |
| Water Solubility | DMSO: 28 mg/mL, soluble |
| Storage Condition | Store at +4°C |
| Packaging | III |
| Application | Enoximone is an inotropic vasodilator and a selective, orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilation and increases intracellular cAMP leve |
| HTC | 2933290090 |
| PubChem ID | 24278408 |
| MDL Number | MFCD00867130 |
| SMILES | CSc1ccc(cc1)C(=O)C2=C(C)NC(=O)N2 |
| InChI | 1S/C12H12N2O2S/c1-7-10(14-12(16)13-7)11(15)8-3-5-9(17-2)6-4-8/h3-6H,1-2H3,(H2,13,14,16) |
| InChI Key | ZJKNESGOIKRXQY-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 41106305 |
| Hazard Symbols | 6.1(b) |
| MSDS | msds/10331_1_77671_31_9.pdf |
| Bioactivity | Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects[1][2][3]. Related Catalog Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Inflammation/Immunology Target PDE3/PDE Ⅲ:5.9 μM (IC50) PDE4A:21.1 μM (IC50, myocardial PDE4A) In Vitro In vitro, 10 μM Enoximone-treated bronchoalveolar lavage (BAL) eosinophils induced by IL-33 treatment shows significantly lower CD11b expression when compared with diluent-treated BAL eosinophils[1]. In Vivo Topical Enoximone (25 μg; intratracheal route) abrogates house dust mite (HDM)-induced allergic airway inflammation[1]. The Enoximone-treated (25 μg; for 5 days) HDM-exposed mice shows significant reductions in inflammatory cell numbers including eosinophils, macrophages, neutrophils, ILC2s, and T cells, indicating that Enoximone treatment reduces airway inflammation[1]. References [1]. Jan Beute, et al. A Pathophysiological Role of PDE3 in Allergic Airway Inflammation. JCI Insight. 2018 Jan 25;3(2):e94888. [2]. R C Dage, et al. Pharmacology and Pharmacokinetics of Enoximone. Cardiology. 1990;77 Suppl 3:2-13; discussion 27-33. [3]. M B Vroom, et al. Effect of Phosphodiesterase Inhibitors on Human Arteries in Vitro. Br J Anaesth. 1996 Jan;76(1):122-9. Chemical & Physical Properties Density 1.3±0.1 g/cm3 Melting Point 255-258°C Molecular Formula C12H12N2O2S Molecular Weight 248.301 Exact Mass 248.061951 PSA 91.02000 LogP 3.72 Appearance of Characters solid | light yellow Index of Refraction 1.645 InChIKey ZJKNESGOIKRXQY-UHFFFAOYSA-N SMILES CSc1ccc(C(=O)c2[nH]c(=O)[nH]c2C)cc1 Storage condition Store at +4°C Water Solubility DMSO: 28 mg/mL, soluble |
| Use of | Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects[1][2][3]. Properties Articles36 Name 4-methyl-5-(4-methylsulfanylbenzoyl)-1,3-dihydroimidazol-2-one Synonym More Synonyms Enoximone Biological Activity Description Enoximone is an inotropic vasodilating agent and a selective and orally active phosphodiesterase III (PDE3) inhibitor with an IC50 of 5.9 μM. Enoximone induces vasodilatation and increases intracellular levels of cAMP by inhibiting cGMP-inhibited PDE. Enoximone also exhibits PDE4 inhibitory effect with an IC50 of 21.1 μM for myocardial PDE4A. Enoximone has the potential for congestive heart failure research and has bronchodilatory, antiasthma and anti-inflammatory effects[1][2][3]. Related Catalog Research Areas >> Cardiovascular Disease Signaling Pathways >> Metabolic Enzyme/Protease >> Phosphodiesterase (PDE) Research Areas >> Inflammation/Immunology PDE4A:21.1 μM (IC50, myocardial PDE4A) In Vitro In vitro, 10 μM Enoximone-treated bronchoalveolar lavage (BAL) eosinophils induced by IL-33 treatment shows significantly lower CD11b expression when compared with diluent-treated BAL eosinophils[1]. In Vivo Topical Enoximone (25 μg; intratracheal route) abrogates house dust mite (HDM)-induced allergic airway inflammation[1]. The Enoximone-treated (25 μg; for 5 days) HDM-exposed mice shows significant reductions in inflammatory cell numbers including eosinophils, macrophages, neutrophils, ILC2s, and T cells, indicating that Enoximone treatment reduces airway inflammation[1]. References [1]. Jan Beute, et al. A Pathophysiological Role of PDE3 in Allergic Airway Inflammation. JCI Insight. 2018 Jan 25;3(2):e94888. [2]. R C Dage, et al. Pharmacology and Pharmacokinetics of Enoximone. Cardiology. 1990;77 Suppl 3:2-13; discussion 27-33. [3]. M B Vroom, et al. Effect of Phosphodiesterase Inhibitors on Human Arteries in Vitro. Br J Anaesth. 1996 Jan;76(1):122-9. Chemical & Physical Properties Molecular Formula C12H12N2O2S Exact Mass 248.061951 PSA 91.02000 Appearance of Characters solid | light yellow Index of Refraction 1.645 InChIKey ZJKNESGOIKRXQY-UHFFFAOYSA-N |
| Tax Rebate | 13.0% |
| Supervision | None. MFN tariff: 6.5%. Ordinary tariff: 20.0% |
| Transport Info | Product name: Purity: 97.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Enlimomab | 142864-19-5 | 2A-9010326 |
| Enlimomab pegol | 169802-84-0 | 2A-9010327 |
| Enloplatin | 111523-41-2 | 2A-9010328 |
| Enocitabine | 55726-47-1 | 2A-9010329 |
| Enoxacin | 74011-58-8 | 2A-9010330 |
| Enprofylline | 41078-02-8 | 2A-9010332 |
| Enprostil | 73121-56-9 | 2A-9010333 |
| Entacapone | 130929-57-6 | 2A-9010335 |
| Entsufon | 55837-16-6 | 2A-9010337 |
| Eperezolid | 165800-04-4 | 2A-9010340 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS